| Identification | Back Directory | [Name]
PF-04971729 | [CAS]
1210344-57-2 | [Synonyms]
CS-186
MK-8835
PF-04971729
Ertugliflozin
PF 04971729-00
Ertugliflozin Base
Ertugliflozin, >=98%
Ertugliflozin MK-8835
PF-04971729 USP/EP/BP
PF-04971729/PF04971729
Leuco methylthioninium
PF-04971729/Ertugliflozin
Ertugliflozin/PF-04971729
Ertugliflozin : PF 04971729-00
ERTUGLIFLOZIN;PF04971729;PF 04971729
PF04971729;PF 04971729 (ERTUGLIFLOZIN)
1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-β-L-idopyranose
β-L-Idopyranose, 1,6-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-
1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose
(1S,2S,3S,4R,5S)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol
(1S,2S,3S,4R,5S)-(2,3,4-TRIS-BENZYLOXY-5-(4-CHLORO-3-(4-ETHOXY-BENZYL)-PHENYL)-68-DIOXA-BICYCLO(3.2.1)OCT-1-YL)-METHANOL
(1S,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol
1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-beta-L-idopyranose PF-04971729(Ertugliflozin) | [Molecular Formula]
C22H25ClO7 | [MDL Number]
MFCD21609259 | [MOL File]
1210344-57-2.mol | [Molecular Weight]
436.88 |
| Chemical Properties | Back Directory | [Melting point ]
65 - 66oC | [Boiling point ]
630.5±55.0 °C(Predicted) | [density ]
1.455 | [storage temp. ]
Sealed in dry,Store in freezer, under -20°C | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
12.95±0.70(Predicted) | [color ]
White to Off-White | [InChIKey]
MCIACXAZCBVDEE-RDZQEHASNA-N | [SMILES]
[C@@]12(C3C=CC(Cl)=C(CC4C=CC(OCC)=CC=4)C=3)OC[C@@](CO)([C@@H](O)[C@H](O)[C@H]1O)O2 |&1:0,20,23,25,27,r| |
| Hazard Information | Back Directory | [Uses]
Ertugliflozin is a sodium/glucose cotransporter 2 (SGLT2) inhibitor used to treat type 2 diabetes. | [Application]
Ertugliflozin is a medication prescribed by veterinarians to help control insulin (blood sugar) levels in horses and ponies with insulin dysregulation (ID), equine metabolic syndrome (EMS), refractory hyperinsulinemia (high blood sugar), and hyperinsulinemic-associated laminitis (HAL), especially for horses that don't respond to changes in diet or other accepted management practices for metabolic syndromes. Ertugliflozin is not FDA-approved for equine use. It falls into the sodium-glucose co-transport-2 (SGLT2) inhibitors category and is administered orally at 0.05?mg/kg once daily for at least 30?days. | [Definition]
ChEBI: Ertugliflozin is a diarylmethane. | [storage]
Store at -20°C | [Mode of action]
Ertugliflozin works by inhibiting the SGLT2 protein, which aids in the reabsorption of glucose in the kidneys, leading to excretion of more glucose through urine. Once daily doses of ertugliflozin have been shown to: Lower blood sugar levels, Correct insulin to normal or near-normal levels, and Reduce abnormal fat pads.
|
|
|